Clinical trial · Observational
Topical Cosmetic Products for Hand and Foot Syndrome
Evaluation of the Efficacy of Topical Cosmetic Products in Patients with Hand and Foot Syndrome (HFS) Undergoing Oncological Treatments
NCT06586073CI-TRIAL-00080530completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the efficacy of a dermocosmetic protocol in reducing the main cutaneous side effects that occur in palmar-plantar erythrodysesthesia syndrome in subjects with a tumor diagnosis, undergoing chemotherapy and targeted treatments such as target therapy and radiotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hand Foot Skin Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cosmetic products | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Diagnosed cancer patients receiving different therapies with hand-foot syndrome skin side effects
- description
- Participants were diagnosed cancer patients receiving chemotherapy and targeted or hormonal treatments. Recruitment was performed by the medical oncologists based on the presence of Hand-foot syndrome (HFS) grade 1 symptoms. The severity of HFS was graded according to the The National Cancer Institute-Common Terminology Criteria for Adverse Events Criteria (NCI-CTCAE) version 5.0. All patients enrolled were provided with a kit of four cosmetic products formulated explicitly for cancer skincare
- interventionNames
- Other: cosmetic products
Primary outcomes (1)
- measure
- Change from Baseline in the mean skin hydration index at 45 days
- timeFrame
- Baseline and 45 days
- description
- Changes from the baseline of skin hydration were assessed using a Corneometer® CM 825 probe that analyze water related changes in the skin's electrical capacitance. All measurements reported are the average of three assessments obtained on two skin areas: the right hand 's dorsum and the right foot's dorsum
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cancer diagnosis undergoing oncological therapy with chemotherapeutic agents, targeted therapy, immunotherapy hormonal treatments * Patients with grade 1 of Hand-foot syndrome (HFS) Male and female patients 18 age or more * Conditions favoring the correct execution of the proposed program * Signature of informed consent, privacy and the form for the use of the data Exclusion Criteria: * Pregnancy or breastfeeding in progress * Other skin toxixities different from HFS * Patients with HFS adverse skin symptoms higher than grade 1 * Psychic or other disorderes * Patients with preexisting skin disorders thet could interfere with thw study results (like dermatitis, prosriais) * Known hypersensitivity or allergy to one of the components of the products
References
Publications (2)
- BACKGROUNDBiswal SG, Mehta RD. Cutaneous Adverse Reactions of Chemotherapy in Cancer Patients: A Clinicoepidemiological Study. Indian J Dermatol. 2018 Jan-Feb;63(1):41-46. doi: 10.4103/ijd.IJD_65_17. PMID 29527024
- BACKGROUNDSaadet ED, Tek I. Evaluation of chemotherapy-induced cutaneous side effects in cancer patients. Int J Dermatol. 2022 Dec;61(12):1519-1526. doi: 10.1111/ijd.16361. Epub 2022 Jul 22. PMID 35867950